20-quarter listed-company comparison

Pharma - MNC bulk Drugs Stocks in India

Pharma - MNC bulk Drugs: Abbott India Ltd owns the largest revenue base; Astrazeneca Pharma India Ltd has the fastest current growth.

The 8 Pharma - MNC bulk Drugs companies listed in India are Abbott India Ltd (₹54.3K Cr, the largest), Glaxosmithkline Pharmaceuticals Ltd, Pfizer Ltd and 5 more. 2 of 8 covered companies beat NIFTY 500 on relative strength. Readings are as of 17 Sep 2026.

All 8 Pharma - MNC bulk Drugs Stocks in India (Sep 2026) — ranked by 4-Factor score

1Procter & Gamble Health Ltd₹9.0K Cr65.6/100Favorable setup · strongest on ROCE and ROCE improvement
2Sanofi Consumer Healthcare India Ltd₹9.3K Cr62.4/100Mixed-positive evidence · strongest on ROCE and profit growth
3Pfizer Ltd₹18.6K Cr56.2/100Mixed-positive evidence · strongest on PEG and own-history P/E
4Glaxosmithkline Pharmaceuticals Ltd₹47.9K Cr54.7/100Mixed-positive evidence · strongest on ROCE and relative strength versus sector
5Abbott India Ltd₹54.3K Cr52.9/100Mixed-positive evidence · strongest on own-history P/E and margin improvement
6Novartis India Ltd₹5.9K Cr47.7/100Mixed-negative evidence · strongest on relative strength versus sector and 13-week relative-strength change
7Sanofi India Ltd₹7.1K Cr46.0/100Mixed-negative evidence · strongest on ROCE improvement and ROCE
8Astrazeneca Pharma India Ltd₹16.9K Cr31.7/100Adverse evidence · strongest on revenue growth and relative strength versus sector

Ranked by the 4-Factor Sector Score (growth & earnings 35, capital efficiency 25, valuation 20, relative strength 20). Prices as of 11 Sep 2026. Not investment advice.

01 · the index people search for

Nifty Pharma - MNC bulk Drugs Index — Constituents & Performance

All 8 listed Indian Pharma - MNC bulk Drugs companies are named here, largest first — the same constituent set people search for as the Nifty Pharma - MNC bulk Drugs index. Every figure is equal-weighted across those companies and carries its own as-of date. One large constituent cannot set the reading.

Abbott India Ltd₹54.3K Cr
Glaxosmithkline Pharmaceuticals Ltd₹47.9K Cr
Pfizer Ltd₹18.6K Cr
Astrazeneca Pharma India Ltd₹16.9K Cr
Sanofi Consumer Healthcare India Ltd₹9.3K Cr
Procter & Gamble Health Ltd₹9.0K Cr
Sanofi India Ltd₹7.1K Cr
Novartis India Ltd₹5.9K Cr

02 · the sector itself · before any single company

How has Pharma - MNC bulk Drugs moved against NIFTY 500?

The line below covers up to 5.2 years and opens on the 5Y view; the buttons cut it shorter. Over the most recent two of them this sector is 2% ahead of NIFTY 500. Earnings across its companies grew 17% on average over the last four reported quarters.

FADING · −1 in 4w~Moving with the index2 of 8 companies ahead of NIFTY 500 by 5% or more over three months1 is 20% or more behind over a year while earnings grew 20% or more

RS ↑2w · 2/8 >200d (−2) · 2/8 lead (−1) · EPS 4/8↑

Pharma - MNC bulk Drugs, equal-weighted, based at 200 NIFTY 500, same base, same start trailing 12-month earnings per share rising falling

Both lines start at 200 in the same week, so the distance between them is the whole story: the sector line is an equal-weighted index of its 8 companies. The bars underneath are trailing 12-month earnings per share, one bar per reported quarter, each member rebased to 100 at the start and the sector taking the median — so a price line pulling away from flat bars is a re-rating, not earnings. A bar turns red when that figure is lower than the quarter before. Rules are fixed and applied identically everywhere on this site: ahead by 5% or more over three months, or behind by 20% or more over a year while earnings grew 20% or more. Hover any point to read both values and the gap. This is a description of what the numbers did, not advice.

03 · sector relative strength, before individual stocks

Is Pharma - MNC bulk Drugs outperforming NIFTY 500?

Pharma - MNC bulk Drugs has outperformed NIFTY 500 by 0% over the last 52 weeks. Over 13 weeks the gap is a lead of 6.5%. 2 of 8 covered companies currently beat NIFTY on Mansfield relative strength, so leadership inside the sector is selective. Novartis India Ltd is the strongest against the sector itself at +107.8%.

+6.5%Sector vs NIFTY 500 · 13 weeks

-0.0%Sector vs NIFTY 500 · 52 weeks

2/8Stocks leading NIFTY 500

3/8Stocks leading sector

Sector metric: 21.0 as of 2026-08-22 · CONSOLIDATION · falling.

The central tension: the companies with the most scale are not necessarily the companies creating the most change.

Start with scale. Then earnings trajectory. Then business quality. Only after those three agree should price leadership carry much weight.

Bottom line

Pharma - MNC bulk Drugs has outperformed NIFTY 500 by 0% over 52 weeks and 6.5% over 13 weeks. 2 of 8 covered companies beat NIFTY on Mansfield relative strength, while 3 of 8 beat the sector itself. Abbott India Ltd leads with revenue of ₹7,005 crore, based on 8 of 8 comparable companies through Jun 2026.

Companies

complete canonical membership

Combined market value

₹1.7 L Cr

Abbott India Ltd

Revenue growing

7/8

positive TTM year-on-year growth

Beating NIFTY 500

2/8

positive Mansfield relative strength

Comparing 5 of 8

04 · research priority, made explicit

4-Factor Sector Score

An additive sector-relative research score. The four displayed point contributions always equal the total: Growth & earnings (35), Capital efficiency (25), Valuation (20), and Relative strength (20). Missing or stale evidence is absorbed inside the affected factor, never applied as a hidden adjustment.

Growth & earnings · 35%Capital efficiency · 25%Valuation · 20%Relative strength · 20%

Procter & Gamble Health Ltd has the strongest current balance of earnings trajectory, business quality, valuation and price confirmation, with 94% evidence confidence.

Glaxosmithkline Pharmaceuticals Ltd has stronger price confirmation than earnings confirmation; that is a research prompt, not permission to chase.

How this score is built, and what the marks mean

Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.

Company	Score	Price stage	Growth & earnings/35	Capital efficiency/25	Valuation/20	Relative strength/20
1Procter & Gamble Health LtdPGHL	65.6/100Favorable setup94% evidence	ASLEEP	25.1/35 Revenue 12.6% · PAT 19.3% · OPM change 0 pp 100% evidence	18.4/25 ROCE 83.9% · OPM 27% 100% evidence	13.3/20 P/E 27× · PEG 1.23 100% evidence	8.8/20 RS sector -2.5% · RS bench -4% · 1Y -16.3%7 of 11 weeks ahead 70% evidence
Exact sum: 25.1 + 18.4 + 13.3 + 8.8 = 65.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
2Sanofi Consumer Healthcare India LtdSANOFICONR	62.4/100Mixed-positive evidence67% evidence	BASING	28.6/35 Revenue 31% · PAT 33% · OPM change 6 pp 71% evidence	20.9/25 ROCE 89.9% · OPM 38% 76% evidence	9.8/20 P/E 34.8× · PEG — 15% evidence	3.1/20 RS sector -15.5% · RS bench -10.4% · 1Y -22.6%0 of 12 weeks ahead 100% evidence
Exact sum: 28.6 + 20.9 + 9.8 + 3.1 = 62.4 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -15.5% and the one-year return is -22.6%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth.
3Pfizer LtdPFIZER	56.2/100Mixed-positive evidence100% evidence	ASLEEP	19.5/35 Revenue 10.6% · PAT -9.2% · OPM change 3 pp 100% evidence	14.5/25 ROCE 24.1% · OPM 38% 100% evidence	19.5/20 P/E 24.2× · PEG 0.73 100% evidence	2.7/20 RS sector -20.1% · RS bench -15.1% · 1Y -20.7%0 of 12 weeks ahead 100% evidence
Exact sum: 19.5 + 14.5 + 19.5 + 2.7 = 56.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
4Glaxosmithkline Pharmaceuticals LtdGLAXO	54.7/100Mixed-positive evidence100% evidence	BREAKING OUT	13.3/35 Revenue 5.8% · PAT 12.4% · OPM change 0 pp 100% evidence	18.0/25 ROCE 61.4% · OPM 31% 100% evidence	5.7/20 P/E 45.5× · PEG 4.12 100% evidence	17.7/20 RS sector 7% · RS bench 13.7% · 1Y 2.1%6 of 12 weeks ahead 100% evidence
Exact sum: 13.3 + 18 + 5.7 + 17.7 = 54.7 · Decision use: Price leads the evidence: RS versus the benchmark is 13.7%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
5Abbott India LtdABBOTINDIA	52.9/100Mixed-positive evidence94% evidence	BASING	18.7/35 Revenue 6.3% · PAT 11.2% · OPM change 3 pp 100% evidence	15.4/25 ROCE 44.8% · OPM 29% 100% evidence	9.3/20 P/E 33.6× · PEG 3.6 100% evidence	9.5/20 RS sector -0.7% · RS bench -6.1% · 1Y -18%3 of 10 weeks ahead 70% evidence
Exact sum: 18.7 + 15.4 + 9.3 + 9.5 = 52.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
6Novartis India LtdNOVARTIND	47.7/100Mixed-negative evidence100% evidence	TURNING	14.1/35 Revenue 5.4% · PAT -4.9% · OPM change 3 pp 100% evidence	7.8/25 ROCE 16.3% · OPM 34% 100% evidence	5.8/20 P/E 60.4× · PEG 1.96 100% evidence	20.0/20 RS sector 107.8% · RS bench 118.6% · 1Y 156.7%10 of 12 weeks ahead 100% evidence
Exact sum: 14.1 + 7.8 + 5.8 + 20 = 47.7 · Decision use: Price leads the evidence: RS versus the benchmark is 118.6%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
7Sanofi India LtdSANOFI	46.0/100Mixed-negative evidence82% evidence	BASING	15.8/35 Revenue -8.9% · PAT -10.5% · OPM change 3 pp 95% evidence	15.8/25 ROCE 57.5% · OPM 26% 76% evidence	10.1/20 P/E 20.7× · PEG — 50% evidence	4.3/20 RS sector -23% · RS bench -18% · 1Y -39.5%0 of 12 weeks ahead 100% evidence
Exact sum: 15.8 + 15.8 + 10.1 + 4.3 = 46 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
8Astrazeneca Pharma India LtdASTRAZEN	31.7/100Adverse evidence87% evidence	ASLEEP	9.8/35 Revenue 31.2% · PAT -7.1% · OPM change -8 pp 100% evidence	8.1/25 ROCE 29.3% · OPM 7% 100% evidence	4.3/20 P/E 97.5× · PEG 3.95 65% evidence	9.5/20 RS sector 2.3% · RS bench -19.4% · 1Y -25.6%0 of 10 weeks ahead 70% evidence
Exact sum: 9.8 + 8.1 + 4.3 + 9.5 = 31.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.

05 · what price has already done

Market action

Novartis India Ltd has the strongest one-year price move in Pharma - MNC bulk Drugs at +156.7%. It also leads on Mansfield relative strength against NIFTY at +118.6%. 2 of 8 covered companies are above zero on that measure. Every line covers 313 weekly closes through 2026-09-11.

Price and relative strength

Every company, the sector's own index and NIFTY 500 all start level on the left edge of the window, so only the distance between the lines counts — the highest line has risen the most since then, and the chart at the top of this page is drawn the same way. It opens on one year; the buttons beside it stretch that to three or five.

06 · the story behind the numbers

Pharma - MNC bulk Drugs — the story behind the numbers

This is the written read behind the Pharma - MNC bulk Drugs figures above — what is actually happening in the sector, in words, with the evidence each claim rests on. It is dated 28 Jul 2026. 4 themes are live here.

The Pharma - MNC bulk Drugs sector shows limited data coverage this week with only 1 constituent, NOVARTIND, reporting results. The demand environment is classified as DETERIORATING based on management commentary. Revenue from operations rose 7.9 percent to Rupees 90.5 crore. The pharmaceutical company recorded improved sales momentum during the quarter.

How old this read is: This read comes from our Pharma - MNC bulk Drugs sector brief dated 28 Jul 2026 — 51 days old. The numbers above it are newer than the words here.

What is live in this sector right now

Live theme	Severity	Evidence on file
Company imports all medicines with no manufacturing footprint in India, making it susceptible to currency fluctuations affecting cost of goods from parent.Named for NOVARTIND	medium	Asset-light model maintains clean balance sheet with low capital expenditure
Company faces potential regulatory pricing caps under National List of Essential Medicines (NLEM) and patent expiry risk with key products like Vymada going off-patent facing…Named for NOVARTIND	medium	Portfolio rationalization and cost optimization measures implemented prior to divestment
Import-dependent business model creates exposure to global supply chain disruptions, though company maintains healthy gross margins from premium product mix.Named for NOVARTIND	low	Leverages parent's global high-quality production network meeting international standards
Parent company Novartis AG involved in patent litigation (Novartis AG vs Natco Pharma), though no specific litigation mentioned for Novartis India Ltd subsidiary itself.Named for NOVARTIND	low	No further detail is on file for this theme.

Sources: our Pharma - MNC bulk Drugs sector brief, 28 Jul 2026.

07 · compare level, then change

Revenue Scale & Growth Durability

Abbott India Ltd has the highest Revenue among the 8 Pharma - MNC bulk Drugs companies compared here, at ₹7,005 crore. Glaxosmithkline Pharmaceuticals Ltd is next at ₹3,954 crore. Astrazeneca Pharma India Ltd has the highest Revenue growth at 31.2%, so level and change sit with different companies. Its Revenue series carries 20 reported observations across the 20-quarter window.

What the numbers say: Abbott India Ltd is the scale leader at ₹7,005 crore, 77.2% ahead of Glaxosmithkline Pharmaceuticals Ltd. Astrazeneca Pharma India Ltd's growth is 31.2% from a ₹2,433 crore base, with 20 reported observations in the 20-quarter window. Treat the growth leader as an acceleration candidate, not as equally proven scale.

LeaderAbbott India Ltd · ₹7,005 crore

Gap77.2% versus #2 · Glaxosmithkline Pharmaceuticals Ltd

Persistence8/8 recent comparable periods

Coverage8/8 companies · 145 observations

Investor read: Abbott India Ltd is the scale benchmark; Astrazeneca Pharma India Ltd is the acceleration watch. Promote the challenger only if growth persists and converts into margin and returns.

This conclusion weakens if: Abbott India Ltd's growth falls below Astrazeneca Pharma India Ltd's for two consecutive comparable reports while operating margin also compresses.

Revenue is compared on a common reported-currency basis. Growth is year-on-year, so seasonality does not masquerade as progress.

Revenuelargest

1Abbott India Ltd ABBOTINDIA₹7.0K Cr

2Glaxosmithkline Pharmaceuticals Ltd GLAXO₹4.0K Cr

3Pfizer Ltd PFIZER₹2.6K Cr

4Astrazeneca Pharma India Ltd ASTRAZEN₹2.4K Cr

5Sanofi India Ltd SANOFI₹1.8K Cr

Revenue growthfastest growers

1Astrazeneca Pharma India Ltd ASTRAZEN31%

2Sanofi Consumer Healthcare India Ltd SANOFICONR31%

3Procter & Gamble Health Ltd PGHL13%

4Pfizer Ltd PFIZER11%

5Abbott India Ltd ABBOTINDIA6.3%

Revenue · company comparison

8/8 level · 8/8 change

On every company-comparison chart on this page: solid lines show level, dotted lines show change when “Both” is selected, and a missing report breaks the line rather than being invented.

All-company data · latest reported quarter

In every all-company table on this page, each figure is the company’s latest single reported quarter. The rankings above them use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.

Company	Revenue	Revenue growth	Reported
Abbott India Ltd ABBOTINDIA	₹1.8K Cr	4.4%	Jun 2026
Glaxosmithkline Pharmaceuticals Ltd GLAXO	₹938 Cr	17%	Jun 2026
Astrazeneca Pharma India Ltd ASTRAZEN	₹683 Cr	30%	Jun 2026
Pfizer Ltd PFIZER	₹653 Cr	8.3%	Jun 2026
Sanofi India Ltd SANOFI	₹438 Cr	7.9%	Jun 2026
Procter & Gamble Health Ltd PGHL	₹364 Cr	7.4%	Jun 2026
Sanofi Consumer Healthcare India Ltd SANOFICONR	₹236 Cr	6.8%	Jun 2026
Novartis India Ltd NOVARTIND	₹104 Cr	18%	Jun 2026

Full 20-quarter history · every available company

Revenue · reported quarter history

Abbott India Ltd · ABBOTINDIA

Sep 2021₹1.2K Cr

Dec 2021₹1.2K Cr

Mar 2022₹1.2K Cr

Jun 2022₹1.3K Cr

Sep 2022₹1.4K Cr

Dec 2022₹1.3K Cr

Mar 2023₹1.3K Cr

Jun 2023₹1.5K Cr

Sep 2023₹1.5K Cr

Dec 2023₹1.4K Cr

Mar 2024₹1.4K Cr

Jun 2024₹1.6K Cr

Sep 2024₹1.6K Cr

Dec 2024₹1.6K Cr

Mar 2025₹1.6K Cr

Jun 2025₹1.7K Cr

Sep 2025₹1.8K Cr

Dec 2025₹1.7K Cr

Mar 2026₹1.7K Cr

Jun 2026₹1.8K Cr

Astrazeneca Pharma India Ltd · ASTRAZEN

Sep 2021₹198 Cr

Dec 2021₹201 Cr

Mar 2022₹232 Cr

Jun 2022₹232 Cr

Sep 2022₹236 Cr

Dec 2022₹250 Cr

Mar 2023₹285 Cr

Jun 2023₹295 Cr

Sep 2023₹311 Cr

Dec 2023₹306 Cr

Mar 2024₹383 Cr

Jun 2024₹388 Cr

Sep 2024₹408 Cr

Dec 2024₹440 Cr

Mar 2025₹480 Cr

Jun 2025₹526 Cr

Sep 2025₹559 Cr

Dec 2025₹612 Cr

Mar 2026₹579 Cr

Jun 2026₹683 Cr

Glaxosmithkline Pharmaceuticals Ltd · GLAXO

Sep 2021₹1.0K Cr

Dec 2021₹816 Cr

Mar 2022₹810 Cr

Jun 2022₹745 Cr

Sep 2022₹917 Cr

Dec 2022₹802 Cr

Mar 2023₹787 Cr

Jun 2023₹762 Cr

Sep 2023₹957 Cr

Dec 2023₹805 Cr

Mar 2024₹930 Cr

Jun 2024₹815 Cr

Sep 2024₹1.0K Cr

Dec 2024₹949 Cr

Mar 2025₹974 Cr

Jun 2025₹805 Cr

Sep 2025₹980 Cr

Dec 2025₹1.0K Cr

Mar 2026₹995 Cr

Jun 2026₹938 Cr

Novartis India Ltd · NOVARTIND

Sep 2021₹104 Cr

Dec 2021₹99 Cr

Mar 2022₹98 Cr

Jun 2022₹121 Cr

Sep 2022₹102 Cr

Dec 2022₹80 Cr

Mar 2023₹76 Cr

Jun 2023₹91 Cr

Sep 2023₹79 Cr

Dec 2023₹85 Cr

Mar 2024₹81 Cr

Jun 2024₹92 Cr

Sep 2024₹87 Cr

Dec 2024₹93 Cr

Mar 2025₹84 Cr

Jun 2025₹88 Cr

Sep 2025₹90 Cr

Dec 2025₹86 Cr

Mar 2026₹91 Cr

Jun 2026₹104 Cr

Pfizer Ltd · PFIZER

Sep 2021₹636 Cr

Dec 2021₹676 Cr

Mar 2022₹550 Cr

Jun 2022₹593 Cr

Sep 2022₹637 Cr

Dec 2022₹622 Cr

Mar 2023₹573 Cr

Jun 2023₹531 Cr

Sep 2023₹575 Cr

Dec 2023₹540 Cr

Mar 2024₹547 Cr

Jun 2024₹563 Cr

Sep 2024₹589 Cr

Dec 2024₹538 Cr

Mar 2025₹592 Cr

Jun 2025₹603 Cr

Sep 2025₹642 Cr

Dec 2025₹645 Cr

Mar 2026₹629 Cr

Jun 2026₹653 Cr

Procter & Gamble Health Ltd · PGHL

Sep 2021₹273 Cr

Dec 2021₹278 Cr

Mar 2022₹268 Cr

Jun 2022₹296 Cr

Sep 2022₹298 Cr

Dec 2022₹310 Cr

Mar 2023₹321 Cr

Jun 2023₹301 Cr

Sep 2023₹305 Cr

Dec 2023₹310 Cr

Mar 2024₹252 Cr

Jun 2024₹284 Cr

Sep 2024₹313 Cr

Dec 2024₹310 Cr

Mar 2025₹311 Cr

Jun 2025₹339 Cr

Sep 2025₹325 Cr

Dec 2025₹374 Cr

Mar 2026₹370 Cr

Jun 2026₹364 Cr

Sanofi Consumer Healthcare India Ltd · SANOFICONR

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023—

Sep 2023₹210 Cr

Dec 2023₹225 Cr

Mar 2024₹222 Cr

Jun 2024₹172 Cr

Sep 2024₹160 Cr

Dec 2024₹171 Cr

Mar 2025₹173 Cr

Jun 2025₹221 Cr

Sep 2025₹234 Cr

Dec 2025₹251 Cr

Mar 2026₹229 Cr

Jun 2026₹236 Cr

Sanofi India Ltd · SANOFI

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023₹515 Cr

Sep 2023₹491 Cr

Dec 2023₹469 Cr

Mar 2024₹511 Cr

Jun 2024₹464 Cr

Sep 2024₹524 Cr

Dec 2024₹515 Cr

Mar 2025₹536 Cr

Jun 2025₹406 Cr

Sep 2025₹475 Cr

Dec 2025₹420 Cr

Mar 2026₹472 Cr

Jun 2026₹438 Cr

Revenue growth · reported quarter history

Abbott India Ltd · ABBOTINDIA

Sep 2021—

Dec 2021—

Mar 2022—

Jun 20227.1%

Sep 202213%

Dec 20228.0%

Mar 20237.5%

Jun 202313%

Sep 20238.3%

Dec 20238.7%

Mar 20247.2%

Jun 20245.3%

Sep 20249.3%

Dec 202412%

Mar 202512%

Jun 202512%

Sep 20257.6%

Dec 20256.8%

Mar 20266.5%

Jun 20264.4%

Astrazeneca Pharma India Ltd · ASTRAZEN

Sep 2021—

Dec 2021—

Mar 2022—

Jun 202233%

Sep 202219%

Dec 202224%

Mar 202323%

Jun 202327%

Sep 202332%

Dec 202322%

Mar 202434%

Jun 202432%

Sep 202431%

Dec 202444%

Mar 202525%

Jun 202536%

Sep 202537%

Dec 202539%

Mar 202621%

Jun 202630%

Glaxosmithkline Pharmaceuticals Ltd · GLAXO

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022-5.7%

Sep 2022-9.2%

Dec 2022-1.7%

Mar 2023-2.8%

Jun 20232.3%

Sep 20234.4%

Dec 20230.4%

Mar 202418%

Jun 20247.0%

Sep 20245.6%

Dec 202418%

Mar 20254.7%

Jun 2025-1.2%

Sep 2025-3.1%

Dec 20259.7%

Mar 20262.2%

Jun 202617%

Novartis India Ltd · NOVARTIND

Sep 2021—

Dec 2021—

Mar 2022—

Jun 202223%

Sep 2022-1.9%

Dec 2022-19%

Mar 2023-22%

Jun 2023-25%

Sep 2023-23%

Dec 20236.3%

Mar 20246.6%

Jun 20241.1%

Sep 202410%

Dec 20249.4%

Mar 20253.7%

Jun 2025-4.4%

Sep 20253.5%

Dec 2025-7.5%

Mar 20268.3%

Jun 202618%

Pfizer Ltd · PFIZER

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022-21%

Sep 20220.2%

Dec 2022-8.0%

Mar 20234.2%

Jun 2023-10%

Sep 2023-9.7%

Dec 2023-13%

Mar 2024-4.5%

Jun 20246.0%

Sep 20242.4%

Dec 2024-0.4%

Mar 20258.2%

Jun 20257.1%

Sep 20259.0%

Dec 202520%

Mar 20266.3%

Jun 20268.3%

Procter & Gamble Health Ltd · PGHL

Sep 2021—

Dec 2021—

Mar 2022—

Jun 20223.9%

Sep 20229.2%

Dec 202212%

Mar 202320%

Jun 20231.7%

Sep 20232.4%

Dec 20230.0%

Mar 2024-22%

Jun 2024-5.7%

Sep 20242.6%

Dec 20240.0%

Mar 202523%

Jun 202519%

Sep 20253.8%

Dec 202521%

Mar 202619%

Jun 20267.4%

Sanofi Consumer Healthcare India Ltd · SANOFICONR

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023—

Sep 2023—

Dec 2023—

Mar 2024—

Jun 2024—

Sep 2024-24%

Dec 2024-24%

Mar 2025-22%

Jun 202528%

Sep 202546%

Dec 202547%

Mar 202632%

Jun 20266.8%

Sanofi India Ltd · SANOFI

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023—

Sep 2023—

Dec 2023—

Mar 2024—

Jun 2024-9.9%

Sep 20246.7%

Dec 20249.8%

Mar 20254.9%

Jun 2025-13%

Sep 2025-9.4%

Dec 2025-18%

Mar 2026-12%

Jun 20267.9%

08 · compare level, then change

Operating Economics & Margin Trend

Pfizer Ltd has the highest OPM among the 8 Pharma - MNC bulk Drugs companies compared here, at 38%. Sanofi Consumer Healthcare India Ltd has the highest Margin change at +6 percentage points, so level and change sit with different companies. 8 of 8 companies report a comparable reading, the latest through Jun 2026.

What the numbers say: Pfizer Ltd leads opm at 38%; Sanofi Consumer Healthcare India Ltd leads margin change at +6 percentage points.

LeaderPfizer Ltd · 38%

Gap0% versus #2 · Sanofi Consumer Healthcare India Ltd

Persistence5/8 recent comparable periods

Coverage8/8 companies · 152 observations

Investor read: Pfizer Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.

This conclusion weakens if: The next two comparable reports reverse the current margin change signal.

Operating margin compares operating profit with revenue. Improvement is measured in percentage points, not percentage growth.

OPMhighest

1Pfizer Ltd PFIZER38%

2Sanofi Consumer Healthcare India Ltd SANOFICONR38%

3Novartis India Ltd NOVARTIND34%

4Glaxosmithkline Pharmaceuticals Ltd GLAXO31%

5Abbott India Ltd ABBOTINDIA29%

Margin changefastest expanders

1Sanofi Consumer Healthcare India Ltd SANOFICONR+6.0 pp

2Abbott India Ltd ABBOTINDIA+3.0 pp

3Novartis India Ltd NOVARTIND+3.0 pp

4Pfizer Ltd PFIZER+3.0 pp

5Sanofi India Ltd SANOFI+3.0 pp

Operating margin · company comparison

8/8 level · 8/8 change

All-company data · latest reported quarter

Company	OPM	Margin change	Reported
Pfizer Ltd PFIZER	38%	+3.0 pp	Jun 2026
Sanofi Consumer Healthcare India Ltd SANOFICONR	38%	+6.0 pp	Jun 2026
Novartis India Ltd NOVARTIND	34%	+3.0 pp	Jun 2026
Glaxosmithkline Pharmaceuticals Ltd GLAXO	31%	0.0 pp	Jun 2026
Abbott India Ltd ABBOTINDIA	29%	+3.0 pp	Jun 2026
Procter & Gamble Health Ltd PGHL	27%	0.0 pp	Jun 2026
Sanofi India Ltd SANOFI	26%	+3.0 pp	Jun 2026
Astrazeneca Pharma India Ltd ASTRAZEN	7.0%	−8.0 pp	Jun 2026

Full 20-quarter history · every available company

OPM · reported quarter history

Abbott India Ltd · ABBOTINDIA

Sep 202121%

Dec 202122%

Mar 202223%

Jun 202221%

Sep 202225%

Dec 202224%

Mar 202321%

Jun 202324%

Sep 202325%

Dec 202327%

Mar 202423%

Jun 202425%

Sep 202427%

Dec 202427%

Mar 202527%

Jun 202526%

Sep 202529%

Dec 202527%

Mar 202628%

Jun 202629%

Astrazeneca Pharma India Ltd · ASTRAZEN

Sep 20219.1%

Dec 20217.3%

Mar 202216%

Jun 202212%

Sep 202217%

Dec 202215%

Mar 202321%

Jun 202323%

Sep 202317%

Dec 20234.9%

Mar 202413%

Jun 202410%

Sep 202413%

Dec 202417%

Mar 202518%

Jun 202515%

Sep 202513%

Dec 20257.0%

Mar 202611%

Jun 20267.0%

Glaxosmithkline Pharmaceuticals Ltd · GLAXO

Sep 202127%

Dec 202124%

Mar 202222%

Jun 202220%

Sep 202228%

Dec 202229%

Mar 202322%

Jun 202319%

Sep 202330%

Dec 202327%

Mar 202428%

Jun 202428%

Sep 202432%

Dec 202431%

Mar 202534%

Jun 202531%

Sep 202534%

Dec 202536%

Mar 202635%

Jun 202631%

Novartis India Ltd · NOVARTIND

Sep 20216.8%

Dec 20216.6%

Mar 20225.7%

Jun 202226%

Sep 202216%

Dec 202210%

Mar 202312%

Jun 202319%

Sep 202321%

Dec 202323%

Mar 202414%

Jun 202426%

Sep 202421%

Dec 202428%

Mar 202529%

Jun 202531%

Sep 202526%

Dec 202526%

Mar 202623%

Jun 202634%

Pfizer Ltd · PFIZER

Sep 202130%

Dec 202129%

Mar 202230%

Jun 202232%

Sep 202236%

Dec 202233%

Mar 202332%

Jun 202321%

Sep 202332%

Dec 202328%

Mar 202435%

Jun 202432%

Sep 202432%

Dec 202427%

Mar 202538%

Jun 202535%

Sep 202536%

Dec 202535%

Mar 202638%

Jun 202638%

Procter & Gamble Health Ltd · PGHL

Sep 202129%

Dec 202122%

Mar 202226%

Jun 202220%

Sep 202231%

Dec 202235%

Mar 202325%

Jun 202315%

Sep 202329%

Dec 202333%

Mar 202427%

Jun 202417%

Sep 202436%

Dec 202440%

Mar 202526%

Jun 202527%

Sep 202537%

Dec 202530%

Mar 202637%

Jun 202627%

Sanofi Consumer Healthcare India Ltd · SANOFICONR

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023—

Sep 202345%

Dec 202340%

Mar 202437%

Jun 202437%

Sep 202439%

Dec 202436%

Mar 202537%

Jun 202532%

Sep 202536%

Dec 202536%

Mar 202639%

Jun 202638%

Sanofi India Ltd · SANOFI

Sep 202126%

Dec 202118%

Mar 202228%

Jun 202223%

Sep 202226%

Dec 202225%

Mar 202331%

Jun 202324%

Sep 202323%

Dec 202321%

Mar 202427%

Jun 202425%

Sep 202423%

Dec 202423%

Mar 202532%

Jun 202523%

Sep 202528%

Dec 202522%

Mar 202630%

Jun 202626%

Margin change · reported quarter history

Abbott India Ltd · ABBOTINDIA

Sep 2021−1.6 pp

Dec 2021−0.1 pp

Mar 2022+4.6 pp

Jun 2022−1.1 pp

Sep 2022+3.6 pp

Dec 2022+2.0 pp

Mar 2023−2.4 pp

Jun 2023+3.3 pp

Sep 2023+0.1 pp

Dec 2023+3.0 pp

Mar 2024+2.0 pp

Jun 2024+1.0 pp

Sep 2024+2.0 pp

Dec 20240.0 pp

Mar 2025+4.0 pp

Jun 2025+1.0 pp

Sep 2025+2.0 pp

Dec 20250.0 pp

Mar 2026+1.0 pp

Jun 2026+3.0 pp

Astrazeneca Pharma India Ltd · ASTRAZEN

Sep 2021−8.0 pp

Dec 2021−8.0 pp

Mar 2022−2.9 pp

Jun 2022+3.1 pp

Sep 2022+8.2 pp

Dec 2022+7.7 pp

Mar 2023+4.6 pp

Jun 2023+11.0 pp

Sep 2023−0.3 pp

Dec 2023−10.1 pp

Mar 2024−8.0 pp

Jun 2024−13.0 pp

Sep 2024−4.0 pp

Dec 2024+12.1 pp

Mar 2025+5.0 pp

Jun 2025+5.0 pp

Sep 20250.0 pp

Dec 2025−10.0 pp

Mar 2026−7.0 pp

Jun 2026−8.0 pp

Glaxosmithkline Pharmaceuticals Ltd · GLAXO

Sep 2021+4.1 pp

Dec 2021+1.4 pp

Mar 2022+0.6 pp

Jun 2022+1.5 pp

Sep 2022+0.6 pp

Dec 2022+4.8 pp

Mar 2023+0.4 pp

Jun 2023−1.0 pp

Sep 2023+2.0 pp

Dec 2023−2.0 pp

Mar 2024+6.0 pp

Jun 2024+9.0 pp

Sep 2024+2.0 pp

Dec 2024+4.0 pp

Mar 2025+6.0 pp

Jun 2025+3.0 pp

Sep 2025+2.0 pp

Dec 2025+5.0 pp

Mar 2026+1.0 pp

Jun 20260.0 pp

Novartis India Ltd · NOVARTIND

Sep 2021−3.9 pp

Dec 2021+9.7 pp

Mar 2022−9.7 pp

Jun 2022+18.3 pp

Sep 2022+9.3 pp

Dec 2022+3.4 pp

Mar 2023+6.3 pp

Jun 2023−7.3 pp

Sep 2023+4.9 pp

Dec 2023+13.0 pp

Mar 2024+2.0 pp

Jun 2024+7.0 pp

Sep 20240.0 pp

Dec 2024+5.0 pp

Mar 2025+15.0 pp

Jun 2025+5.0 pp

Sep 2025+5.0 pp

Dec 2025−2.0 pp

Mar 2026−6.0 pp

Jun 2026+3.0 pp

Pfizer Ltd · PFIZER

Sep 2021−4.4 pp

Dec 2021−4.3 pp

Mar 2022+6.6 pp

Jun 2022−5.8 pp

Sep 2022+6.6 pp

Dec 2022+4.1 pp

Mar 2023+1.9 pp

Jun 2023−11.4 pp

Sep 2023−4.4 pp

Dec 2023−5.0 pp

Mar 2024+3.0 pp

Jun 2024+11.0 pp

Sep 20240.0 pp

Dec 2024−1.0 pp

Mar 2025+3.0 pp

Jun 2025+3.0 pp

Sep 2025+4.0 pp

Dec 2025+8.0 pp

Mar 20260.0 pp

Jun 2026+3.0 pp

Procter & Gamble Health Ltd · PGHL

Sep 2021−1.0 pp

Dec 2021−14.7 pp

Mar 2022+11.7 pp

Jun 2022+3.0 pp

Sep 2022+1.9 pp

Dec 2022+12.8 pp

Mar 2023−0.7 pp

Jun 2023−5.0 pp

Sep 2023−1.5 pp

Dec 2023−2.0 pp

Mar 2024+2.0 pp

Jun 2024+2.0 pp

Sep 2024+7.0 pp

Dec 2024+7.0 pp

Mar 2025−1.0 pp

Jun 2025+10.0 pp

Sep 2025+1.0 pp

Dec 2025−10.0 pp

Mar 2026+11.0 pp

Jun 20260.0 pp

Sanofi Consumer Healthcare India Ltd · SANOFICONR

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023—

Sep 2023—

Dec 2023—

Mar 2024—

Jun 2024—

Sep 2024−6.0 pp

Dec 2024−4.0 pp

Mar 20250.0 pp

Jun 2025−5.0 pp

Sep 2025−3.0 pp

Dec 20250.0 pp

Mar 2026+2.0 pp

Jun 2026+6.0 pp

Sanofi India Ltd · SANOFI

Sep 2021−1.6 pp

Dec 2021−4.7 pp

Mar 2022+1.4 pp

Jun 2022−8.3 pp

Sep 2022−0.1 pp

Dec 2022+6.4 pp

Mar 2023+3.7 pp

Jun 2023+1.0 pp

Sep 2023−3.3 pp

Dec 2023−3.8 pp

Mar 2024−4.2 pp

Jun 2024+1.0 pp

Sep 20240.0 pp

Dec 2024+2.0 pp

Mar 2025+5.0 pp

Jun 2025−2.0 pp

Sep 2025+5.0 pp

Dec 2025−1.0 pp

Mar 2026−2.0 pp

Jun 2026+3.0 pp

09 · compare level, then change

Profit Scale & Acceleration

Abbott India Ltd has the highest Net profit among the 8 Pharma - MNC bulk Drugs companies compared here, at ₹1,615 crore. Glaxosmithkline Pharmaceuticals Ltd is next at ₹1,068 crore. Sanofi Consumer Healthcare India Ltd has the highest Profit growth at 33%, so level and change sit with different companies.

What the numbers say: Abbott India Ltd leads with ₹1,615 crore of TTM profit, 51.2% above Glaxosmithkline Pharmaceuticals Ltd. Sanofi Consumer Healthcare India Ltd shows 33% growth from a ₹266 crore profit base. Compare the size of the base and persistence before ranking acceleration above profit scale.

LeaderAbbott India Ltd · ₹1,615 crore

Gap51.2% versus #2 · Glaxosmithkline Pharmaceuticals Ltd

Persistence8/8 recent comparable periods

Coverage8/8 companies · 145 observations

Investor read: Abbott India Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.

This conclusion weakens if: The next two comparable reports reverse the current profit growth signal.

Net profit is the residual after operating costs, interest and tax. Growth off a loss or near-zero base is excluded from the fastest-grower rank.

Net profitlargest

1Abbott India Ltd ABBOTINDIA₹1.6K Cr

2Glaxosmithkline Pharmaceuticals Ltd GLAXO₹1.1K Cr

3Pfizer Ltd PFIZER₹735 Cr

4Procter & Gamble Health Ltd PGHL₹358 Cr

5Sanofi India Ltd SANOFI₹325 Cr

Profit growthfastest growers

1Sanofi Consumer Healthcare India Ltd SANOFICONR33%

2Procter & Gamble Health Ltd PGHL19%

3Glaxosmithkline Pharmaceuticals Ltd GLAXO12%

4Abbott India Ltd ABBOTINDIA11%

5Novartis India Ltd NOVARTIND-4.9%

Net profit · company comparison

8/8 level · 8/8 change

All-company data · latest reported quarter

Company	Net profit	Profit growth	Reported
Abbott India Ltd ABBOTINDIA	₹429 Cr	17%	Jun 2026
Glaxosmithkline Pharmaceuticals Ltd GLAXO	₹237 Cr	16%	Jun 2026
Pfizer Ltd PFIZER	₹204 Cr	6.3%	Jun 2026
Procter & Gamble Health Ltd PGHL	₹96 Cr	45%	Jun 2026
Sanofi India Ltd SANOFI	₹84 Cr	20%	Jun 2026
Sanofi Consumer Healthcare India Ltd SANOFICONR	₹69 Cr	13%	Jun 2026
Astrazeneca Pharma India Ltd ASTRAZEN	₹38 Cr	-32%	Jun 2026
Novartis India Ltd NOVARTIND	₹32 Cr	14%	Jun 2026

Full 20-quarter history · every available company

Net profit · reported quarter history

Abbott India Ltd · ABBOTINDIA

Sep 2021₹192 Cr

Dec 2021₹199 Cr

Mar 2022₹211 Cr

Jun 2022₹206 Cr

Sep 2022₹266 Cr

Dec 2022₹247 Cr

Mar 2023₹231 Cr

Jun 2023₹290 Cr

Sep 2023₹313 Cr

Dec 2023₹311 Cr

Mar 2024₹287 Cr

Jun 2024₹328 Cr

Sep 2024₹359 Cr

Dec 2024₹361 Cr

Mar 2025₹367 Cr

Jun 2025₹366 Cr

Sep 2025₹415 Cr

Dec 2025₹376 Cr

Mar 2026₹395 Cr

Jun 2026₹429 Cr

Astrazeneca Pharma India Ltd · ASTRAZEN

Sep 2021₹12 Cr

Dec 2021₹11 Cr

Mar 2022₹28 Cr

Jun 2022₹20 Cr

Sep 2022₹33 Cr

Dec 2022₹29 Cr

Mar 2023₹17 Cr

Jun 2023₹54 Cr

Sep 2023₹52 Cr

Dec 2023₹16 Cr

Mar 2024₹39 Cr

Jun 2024₹-12 Cr

Sep 2024₹38 Cr

Dec 2024₹31 Cr

Mar 2025₹58 Cr

Jun 2025₹56 Cr

Sep 2025₹54 Cr

Dec 2025₹33 Cr

Mar 2026₹45 Cr

Jun 2026₹38 Cr

Glaxosmithkline Pharmaceuticals Ltd · GLAXO

Sep 2021₹204 Cr

Dec 2021₹150 Cr

Mar 2022₹1.2K Cr

Jun 2022₹119 Cr

Sep 2022₹193 Cr

Dec 2022₹165 Cr

Mar 2023₹133 Cr

Jun 2023₹132 Cr

Sep 2023₹218 Cr

Dec 2023₹46 Cr

Mar 2024₹194 Cr

Jun 2024₹182 Cr

Sep 2024₹252 Cr

Dec 2024₹230 Cr

Mar 2025₹263 Cr

Jun 2025₹205 Cr

Sep 2025₹257 Cr

Dec 2025₹296 Cr

Mar 2026₹278 Cr

Jun 2026₹237 Cr

Novartis India Ltd · NOVARTIND

Sep 2021₹7 Cr

Dec 2021₹6 Cr

Mar 2022₹-23 Cr

Jun 2022₹52 Cr

Sep 2022₹18 Cr

Dec 2022₹8 Cr

Mar 2023₹25 Cr

Jun 2023₹20 Cr

Sep 2023₹24 Cr

Dec 2023₹27 Cr

Mar 2024₹15 Cr

Jun 2024₹26 Cr

Sep 2024₹20 Cr

Dec 2024₹25 Cr

Mar 2025₹29 Cr

Jun 2025₹28 Cr

Sep 2025₹24 Cr

Dec 2025₹16 Cr

Mar 2026₹25 Cr

Jun 2026₹32 Cr

Pfizer Ltd · PFIZER

Sep 2021₹143 Cr

Dec 2021₹144 Cr

Mar 2022₹126 Cr

Jun 2022₹33 Cr

Sep 2022₹311 Cr

Dec 2022₹151 Cr

Mar 2023₹130 Cr

Jun 2023₹94 Cr

Sep 2023₹149 Cr

Dec 2023₹130 Cr

Mar 2024₹179 Cr

Jun 2024₹151 Cr

Sep 2024₹158 Cr

Dec 2024₹128 Cr

Mar 2025₹331 Cr

Jun 2025₹192 Cr

Sep 2025₹189 Cr

Dec 2025₹142 Cr

Mar 2026₹200 Cr

Jun 2026₹204 Cr

Procter & Gamble Health Ltd · PGHL

Sep 2021₹55 Cr

Dec 2021₹45 Cr

Mar 2022₹51 Cr

Jun 2022₹41 Cr

Sep 2022₹64 Cr

Dec 2022₹77 Cr

Mar 2023₹59 Cr

Jun 2023₹30 Cr

Sep 2023₹66 Cr

Dec 2023₹72 Cr

Mar 2024₹47 Cr

Jun 2024₹17 Cr

Sep 2024₹82 Cr

Dec 2024₹91 Cr

Mar 2025₹61 Cr

Jun 2025₹66 Cr

Sep 2025₹89 Cr

Dec 2025₹78 Cr

Mar 2026₹95 Cr

Jun 2026₹96 Cr

Sanofi Consumer Healthcare India Ltd · SANOFICONR

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023—

Sep 2023₹71 Cr

Dec 2023₹68 Cr

Mar 2024₹63 Cr

Jun 2024₹29 Cr

Sep 2024₹45 Cr

Dec 2024₹44 Cr

Mar 2025₹50 Cr

Jun 2025₹61 Cr

Sep 2025₹63 Cr

Dec 2025₹66 Cr

Mar 2026₹68 Cr

Jun 2026₹69 Cr

Sanofi India Ltd · SANOFI

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023₹123 Cr

Sep 2023₹152 Cr

Dec 2023₹138 Cr

Mar 2024₹137 Cr

Jun 2024₹103 Cr

Sep 2024₹82 Cr

Dec 2024₹91 Cr

Mar 2025₹120 Cr

Jun 2025₹70 Cr

Sep 2025₹76 Cr

Dec 2025₹62 Cr

Mar 2026₹103 Cr

Jun 2026₹84 Cr

Profit growth · reported quarter history

Abbott India Ltd · ABBOTINDIA

Sep 2021—

Dec 2021—

Mar 2022—

Jun 20225.1%

Sep 202239%

Dec 202224%

Mar 20239.5%

Jun 202341%

Sep 202318%

Dec 202326%

Mar 202424%

Jun 202413%

Sep 202415%

Dec 202416%

Mar 202528%

Jun 202512%

Sep 202516%

Dec 20254.2%

Mar 20267.6%

Jun 202617%

Astrazeneca Pharma India Ltd · ASTRAZEN

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022100%

Sep 2022175%

Dec 2022164%

Mar 2023-39%

Jun 2023170%

Sep 202358%

Dec 2023-45%

Mar 2024129%

Jun 2024-122%

Sep 2024-27%

Dec 202494%

Mar 202549%

Jun 2025—

Sep 202542%

Dec 20256.5%

Mar 2026-22%

Jun 2026-32%

Glaxosmithkline Pharmaceuticals Ltd · GLAXO

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022-1.7%

Sep 2022-5.4%

Dec 202210%

Mar 2023-89%

Jun 202311%

Sep 202313%

Dec 2023-72%

Mar 202446%

Jun 202438%

Sep 202416%

Dec 2024400%

Mar 202536%

Jun 202513%

Sep 20252.0%

Dec 202529%

Mar 20265.7%

Jun 202616%

Novartis India Ltd · NOVARTIND

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022767%

Sep 2022157%

Dec 202233%

Mar 2023—

Jun 2023-62%

Sep 202333%

Dec 2023238%

Mar 2024-40%

Jun 202430%

Sep 2024-17%

Dec 2024-7.4%

Mar 202593%

Jun 20257.7%

Sep 202520%

Dec 2025-36%

Mar 2026-14%

Jun 202614%

Pfizer Ltd · PFIZER

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022-84%

Sep 2022117%

Dec 20224.9%

Mar 20233.2%

Jun 2023185%

Sep 2023-52%

Dec 2023-14%

Mar 202438%

Jun 202461%

Sep 20246.0%

Dec 2024-1.5%

Mar 202585%

Jun 202527%

Sep 202520%

Dec 202511%

Mar 2026-40%

Jun 20266.3%

Procter & Gamble Health Ltd · PGHL

Sep 2021—

Dec 2021—

Mar 2022—

Jun 202221%

Sep 202216%

Dec 202271%

Mar 202316%

Jun 2023-27%

Sep 20233.1%

Dec 2023-6.5%

Mar 2024-20%

Jun 2024-43%

Sep 202424%

Dec 202426%

Mar 202530%

Jun 2025288%

Sep 20258.5%

Dec 2025-14%

Mar 202656%

Jun 202645%

Sanofi Consumer Healthcare India Ltd · SANOFICONR

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023—

Sep 2023—

Dec 2023—

Mar 2024—

Jun 2024—

Sep 2024-37%

Dec 2024-35%

Mar 2025-21%

Jun 2025110%

Sep 202540%

Dec 202550%

Mar 202636%

Jun 202613%

Sanofi India Ltd · SANOFI

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023—

Sep 2023—

Dec 2023—

Mar 2024—

Jun 2024-16%

Sep 2024-46%

Dec 2024-34%

Mar 2025-12%

Jun 2025-32%

Sep 2025-7.3%

Dec 2025-32%

Mar 2026-14%

Jun 202620%

10 · compare level, then change

Return On Capital Employed

Sanofi Consumer Healthcare India Ltd has the highest ROCE among the 8 Pharma - MNC bulk Drugs companies compared here, at 89.9%. Procter & Gamble Health Ltd is next at 83.9%. Procter & Gamble Health Ltd has the highest ROCE change at +14.6 percentage points, so level and change sit with different companies.

What the numbers say: Sanofi Consumer Healthcare India Ltd leads ROCE at 89.9%, 6 percentage points above Procter & Gamble Health Ltd. Procter & Gamble Health Ltd has the strongest latest improvement at +14.6 percentage points. Read the leader beside the density of its reported history: a sparse high return is a candidate; a repeated high return is evidence of durability.

LeaderSanofi Consumer Healthcare India Ltd · 89.9%

Gap7.2% versus #2 · Procter & Gamble Health Ltd

PersistenceNot enough history

Coverage8/8 companies · 89 observations

Investor read: Sanofi Consumer Healthcare India Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.

This conclusion weakens if: The next two comparable reports reverse the current roce change signal.

ROCE asks how much operating return the business earns on the capital employed. Direction matters, but a single exceptional year should not be mistaken for durability.

ROCEhighest

1Sanofi Consumer Healthcare India Ltd SANOFICONR90%

2Procter & Gamble Health Ltd PGHL84%

3Glaxosmithkline Pharmaceuticals Ltd GLAXO61%

4Sanofi India Ltd SANOFI58%

5Abbott India Ltd ABBOTINDIA45%

ROCE changefastest improvers

1Procter & Gamble Health Ltd PGHL+14.6 pp

2Sanofi India Ltd SANOFI+9.0 pp

3Pfizer Ltd PFIZER+4.0 pp

4Abbott India Ltd ABBOTINDIA0.0 pp

5Novartis India Ltd NOVARTIND0.0 pp

Return on capital · company comparison

8/8 level · 7/8 change

Withheld from this chart: Sanofi Consumer Healthcare India Ltd (SANOFICONR) — its two data sources disagree by up to 132% on reported income across 11 comparable periods, so its derived ratios are withheld; Sanofi India Ltd (SANOFI) — its two data sources disagree by up to 45% on reported income across 11 comparable periods, so its derived ratios are withheld. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.

All-company data · latest reported quarter

Company	ROCE	ROCE change	Reported
Procter & Gamble Health Ltd PGHL	74%	+14.6 pp	Jun 2026
Glaxosmithkline Pharmaceuticals Ltd GLAXO	49%	−1.6 pp	Jun 2026
Abbott India Ltd ABBOTINDIA	36%	0.0 pp	Jun 2026
Astrazeneca Pharma India Ltd ASTRAZEN	23%	−3.2 pp	Jun 2026
Pfizer Ltd PFIZER	20%	+4.0 pp	Jun 2026
Novartis India Ltd NOVARTIND	11%	0.0 pp	Jun 2026

Full 20-quarter history · every available company

ROCE · reported quarter history

Abbott India Ltd · ABBOTINDIA

Sep 202135%

Dec 2021—

Mar 202234%

Jun 2022—

Sep 202238%

Dec 2022—

Mar 202334%

Jun 2023—

Sep 202339%

Dec 202350%

Mar 202436%

Jun 202447%

Sep 202440%

Dec 202452%

Mar 202536%

Jun 202547%

Sep 202541%

Dec 202552%

Mar 202636%

Jun 2026—

Astrazeneca Pharma India Ltd · ASTRAZEN

Sep 2021—

Dec 2021—

Mar 202213%

Jun 2022—

Sep 202219%

Dec 2022—

Mar 202325%

Jun 2023—

Sep 202330%

Dec 202331%

Mar 202424%

Jun 202420%

Sep 202418%

Dec 202418%

Mar 202526%

Jun 202532%

Sep 202533%

Dec 202535%

Mar 202623%

Jun 2026—

Glaxosmithkline Pharmaceuticals Ltd · GLAXO

Sep 202137%

Dec 2021—

Mar 202225%

Jun 2022—

Sep 202242%

Dec 2022—

Mar 202337%

Jun 2023—

Sep 202343%

Dec 202342%

Mar 202441%

Jun 202444%

Sep 202450%

Dec 202463%

Mar 202551%

Jun 202561%

Sep 202558%

Dec 202571%

Mar 202649%

Jun 2026—

Novartis India Ltd · NOVARTIND

Sep 20212.2%

Dec 2021—

Mar 20223.2%

Jun 2022—

Sep 20227.5%

Dec 2022—

Mar 20237.3%

Jun 2023—

Sep 20236.4%

Dec 202316%

Mar 20248.2%

Jun 202416%

Sep 202410%

Dec 202416%

Mar 202511%

Jun 202517%

Sep 202512%

Dec 202518%

Mar 202611%

Jun 2026—

Pfizer Ltd · PFIZER

Sep 202126%

Dec 2021—

Mar 202224%

Jun 2022—

Sep 202222%

Dec 2022—

Mar 202321%

Jun 2023—

Sep 202318%

Dec 202321%

Mar 202416%

Jun 202424%

Sep 202417%

Dec 202423%

Mar 202516%

Jun 202527%

Sep 202519%

Dec 202529%

Mar 202620%

Jun 2026—

Procter & Gamble Health Ltd · PGHL

Sep 2021—

Dec 202130%

Mar 2022—

Jun 202237%

Sep 2022—

Dec 202238%

Mar 2023—

Jun 202337%

Sep 202344%

Dec 202337%

Mar 202436%

Jun 202433%

Sep 202436%

Dec 202438%

Mar 202559%

Jun 202556%

Sep 202558%

Dec 202552%

Mar 202674%

Jun 2026—

ROCE change · reported quarter history

Abbott India Ltd · ABBOTINDIA

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022+3.3 pp

Dec 2022—

Mar 2023+0.2 pp

Jun 2023—

Sep 2023+0.5 pp

Dec 2023—

Mar 2024+2.0 pp

Jun 2024—

Sep 2024+1.6 pp

Dec 2024+1.7 pp

Mar 2025+0.1 pp

Jun 2025+0.2 pp

Sep 2025+0.5 pp

Dec 2025−0.3 pp

Mar 20260.0 pp

Jun 2026—

Astrazeneca Pharma India Ltd · ASTRAZEN

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023+11.6 pp

Jun 2023—

Sep 2023+11.0 pp

Dec 2023—

Mar 2024−1.0 pp

Jun 2024—

Sep 2024−12.3 pp

Dec 2024−12.4 pp

Mar 2025+2.6 pp

Jun 2025+12.2 pp

Sep 2025+15.0 pp

Dec 2025+16.1 pp

Mar 2026−3.2 pp

Jun 2026—

Glaxosmithkline Pharmaceuticals Ltd · GLAXO

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022+4.9 pp

Dec 2022—

Mar 2023+12.3 pp

Jun 2023—

Sep 2023+1.0 pp

Dec 2023—

Mar 2024+3.9 pp

Jun 2024—

Sep 2024+6.8 pp

Dec 2024+21.0 pp

Mar 2025+9.3 pp

Jun 2025+17.1 pp

Sep 2025+8.1 pp

Dec 2025+8.4 pp

Mar 2026−1.6 pp

Jun 2026—

Novartis India Ltd · NOVARTIND

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022+5.3 pp

Dec 2022—

Mar 2023+4.1 pp

Jun 2023—

Sep 2023−1.1 pp

Dec 2023—

Mar 2024+0.9 pp

Jun 2024—

Sep 2024+3.9 pp

Dec 2024−0.5 pp

Mar 2025+2.9 pp

Jun 2025+0.8 pp

Sep 2025+1.5 pp

Dec 2025+1.6 pp

Mar 20260.0 pp

Jun 2026—

Pfizer Ltd · PFIZER

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022−3.7 pp

Dec 2022—

Mar 2023−2.6 pp

Jun 2023—

Sep 2023−4.3 pp

Dec 2023—

Mar 2024−5.4 pp

Jun 2024—

Sep 2024−0.7 pp

Dec 2024+2.3 pp

Mar 20250.0 pp

Jun 2025+3.1 pp

Sep 2025+2.2 pp

Dec 2025+5.9 pp

Mar 2026+4.0 pp

Jun 2026—

Procter & Gamble Health Ltd · PGHL

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022+7.7 pp

Mar 2023—

Jun 2023+0.1 pp

Sep 2023—

Dec 2023−1.1 pp

Mar 2024—

Jun 2024−3.7 pp

Sep 2024−7.3 pp

Dec 2024+0.7 pp

Mar 2025+23.2 pp

Jun 2025+22.9 pp

Sep 2025+22.2 pp

Dec 2025+14.5 pp

Mar 2026+14.6 pp

Jun 2026—

11 · compare level, then change

Valuation Against Growth & Quality

Pfizer Ltd has the lowest PEG among the 8 Pharma - MNC bulk Drugs companies compared here, at 0.73×. Procter & Gamble Health Ltd is next at 1.23×. Sanofi India Ltd has the lowest P/E at 20.7×, so level and change sit with different companies. 6 of 8 companies report a comparable reading, the latest through Jun 2026.

What the numbers say: Pfizer Ltd has the lowest comparable PEG at 0.73×, 40.7% below Procter & Gamble Health Ltd. Only 6 of 8 companies have earnings and growth steady enough for the ratio to mean anything, so no broad “cheapest stock” conclusion is defensible unless the current multiple, own-history position and growth durability agree.

LeaderPfizer Ltd · 0.73×

Gap40.7% versus #2 · Procter & Gamble Health Ltd

Persistence0/8 recent comparable periods

Coverage6/8 companies · 63 observations

Investor read: Treat valuation as permission to investigate, never as a standalone reason to buy.

This conclusion weakens if: The next two comparable reports reverse the current p/e signal.

PEG is shown only when earnings are positive and three-year EPS growth is between 5% and 60%. It is recomputed consistently as the trailing P/E divided by that growth rate — reported earnings, never an expected-earnings multiple. On Indian companies it is shown only where the two data feeds agreed. Where any of that fails the ratio is left out rather than printed: a P/E divided by a loss, or by growth measured off a tiny base, is a number that looks precise and means nothing.

PEGlowest PEG

1Pfizer Ltd PFIZER0.7

2Procter & Gamble Health Ltd PGHL1.2

3Novartis India Ltd NOVARTIND2.0

4Abbott India Ltd ABBOTINDIA3.6

5Astrazeneca Pharma India Ltd ASTRAZEN4.0

P/Elowest P/E

1Sanofi India Ltd SANOFI20.7

2Pfizer Ltd PFIZER24.2

3Procter & Gamble Health Ltd PGHL27.0

4Abbott India Ltd ABBOTINDIA33.6

5Sanofi Consumer Healthcare India Ltd SANOFICONR34.8

Valuation · company comparison

6/8 level · 8/8 change

All-company data · latest reported quarter

Company	PEG	P/E	Reported
Glaxosmithkline Pharmaceuticals Ltd GLAXO	4.1	41.5	Jun 2026
Astrazeneca Pharma India Ltd ASTRAZEN	4.0	109.6	Jun 2026
Abbott India Ltd ABBOTINDIA	3.6	35.0	Jun 2026
Novartis India Ltd NOVARTIND	2.0	38.1	Jun 2026
Procter & Gamble Health Ltd PGHL	1.2	31.6	Jun 2026
Pfizer Ltd PFIZER	0.7	27.0	Jun 2026
Sanofi Consumer Healthcare India Ltd SANOFICONR	—	42.1	Jun 2026
Sanofi India Ltd SANOFI	—	23.5	Jun 2026

Full 20-quarter history · every available company

PEG · reported quarter history

Abbott India Ltd · ABBOTINDIA

Sep 202112.1

Dec 20214.6

Mar 20223.3

Jun 20223.1

Sep 20223.0

Dec 20222.2

Mar 20235.3

Jun 20231.3

Sep 20231.7

Dec 20232.0

Mar 20242.1

Jun 20243.8

Sep 20242.5

Dec 20242.6

Mar 20253.0

Jun 20253.0

Sep 20252.5

Dec 20252.3

Mar 20262.6

Jun 20263.6

Astrazeneca Pharma India Ltd · ASTRAZEN

Sep 20214.0

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023—

Sep 2023—

Dec 2023—

Mar 2024—

Jun 2024—

Sep 2024—

Dec 2024—

Mar 202525.3

Jun 2025—

Sep 20253.1

Dec 202516.8

Mar 20264.0

Jun 2026—

Glaxosmithkline Pharmaceuticals Ltd · GLAXO

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 20225.8

Mar 2023—

Jun 2023—

Sep 20230.9

Dec 2023—

Mar 20241.1

Jun 20246.0

Sep 20243.7

Dec 20241.9

Mar 20251.6

Jun 20252.0

Sep 2025—

Dec 20252.3

Mar 20266.7

Jun 20264.1

Novartis India Ltd · NOVARTIND

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023—

Sep 2023—

Dec 2023—

Mar 2024—

Jun 20241.2

Sep 20241.2

Dec 2024—

Mar 2025—

Jun 20253.3

Sep 20251.6

Dec 2025—

Mar 20262.0

Jun 2026—

Pfizer Ltd · PFIZER

Sep 20214.5

Dec 20212.3

Mar 20221.4

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023—

Sep 2023—

Dec 2023—

Mar 20241.0

Jun 2024—

Sep 20247.0

Dec 20242.5

Mar 2025—

Jun 2025—

Sep 20252.7

Dec 20252.1

Mar 20261.2

Jun 20260.7

Procter & Gamble Health Ltd · PGHL

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 20224.0

Dec 20222.8

Mar 20230.6

Jun 20231.2

Sep 20231.9

Dec 20231.8

Mar 2024—

Jun 2024—

Sep 2024—

Dec 2024—

Mar 20254.2

Jun 20251.8

Sep 20250.8

Dec 20250.9

Mar 20260.5

Jun 20261.2

P/E · reported quarter history

Abbott India Ltd · ABBOTINDIA

Sep 202163.8

Dec 202157.7

Mar 202246.0

Jun 202248.0

Sep 202250.3

Dec 202251.5

Mar 202350.5

Jun 202352.4

Sep 202347.6

Dec 202344.9

Mar 202450.3

Jun 202448.9

Sep 202450.2

Dec 202448.4

Mar 202548.9

Jun 202552.5

Sep 202543.5

Dec 202540.7

Mar 202636.4

Jun 202635.0

Astrazeneca Pharma India Ltd · ASTRAZEN

Sep 202190.8

Dec 2021109.8

Mar 2022107.3

Jun 2022111.0

Sep 2022108.8

Dec 202289.5

Mar 202373.9

Jun 202370.7

Sep 202368.3

Dec 202379.9

Mar 202483.5

Jun 2024104.3

Sep 2024137.1

Dec 2024123.5

Mar 2025128.4

Jun 2025117.0

Sep 2025104.2

Dec 202596.0

Mar 202695.3

Jun 2026109.6

Glaxosmithkline Pharmaceuticals Ltd · GLAXO

Sep 202163.8

Dec 202163.1

Mar 202255.0

Jun 202261.1

Sep 202258.8

Dec 202253.9

Mar 202351.6

Jun 202340.9

Sep 202342.9

Dec 202350.5

Mar 202451.4

Jun 202468.4

Sep 202459.3

Dec 202448.1

Mar 202557.1

Jun 202566.7

Sep 202547.8

Dec 202543.8

Mar 202638.1

Jun 202641.5

Novartis India Ltd · NOVARTIND

Sep 202188.8

Dec 202185.9

Mar 202251.3

Jun 202235.0

Sep 202218.7

Dec 202216.5

Mar 202313.6

Jun 202319.4

Sep 202324.9

Dec 202324.9

Mar 202426.6

Jun 202432.0

Sep 202431.7

Dec 202426.5

Mar 202522.5

Jun 202524.5

Sep 202521.0

Dec 202518.2

Mar 202624.9

Jun 202638.1

Pfizer Ltd · PFIZER

Sep 202145.6

Dec 202139.6

Mar 202234.3

Jun 202230.6

Sep 202235.1

Dec 202234.8

Mar 202326.9

Jun 202328.5

Sep 202331.7

Dec 202336.5

Mar 202437.8

Jun 202438.0

Sep 202444.3

Dec 202436.4

Mar 202529.8

Jun 202541.0

Sep 202533.4

Dec 202532.7

Mar 202628.2

Jun 202627.0

Procter & Gamble Health Ltd · PGHL

Sep 202150.6

Dec 202151.2

Mar 202246.8

Jun 202236.3

Sep 202235.4

Dec 202232.7

Mar 202333.4

Jun 202336.2

Sep 202337.0

Dec 202335.5

Mar 202434.5

Jun 202439.2

Sep 202443.7

Dec 202438.7

Mar 202534.8

Jun 202537.8

Sep 202534.7

Dec 202530.5

Mar 202627.5

Jun 202631.6

Sanofi Consumer Healthcare India Ltd · SANOFICONR

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023—

Sep 2023—

Dec 2023—

Mar 2024—

Jun 2024—

Sep 2024—

Dec 2024—

Mar 2025—

Jun 202557.3

Sep 202556.5

Dec 202551.2

Mar 202640.0

Jun 202642.1

Sanofi India Ltd · SANOFI

Sep 202119.9

Dec 202118.4

Mar 202218.0

Jun 202215.5

Sep 202215.5

Dec 202216.7

Mar 202315.4

Jun 202317.7

Sep 202319.9

Dec 202324.7

Mar 202428.0

Jun 202444.0

Sep 202444.1

Dec 202439.8

Mar 202535.7

Jun 202537.5

Sep 202530.6

Dec 202525.5

Mar 202621.2

Jun 202623.5

12 · before the conclusion, check the blind spots

What can make this comparison misleading?

This Pharma - MNC bulk Drugs comparison names 5 specific ways its own evidence can mislead, all listed below. All 8 companies here report on comparable dates, so no rank carries a stale marker. 2 have second-feed figures withheld because the two sources disagree. A high growth rate can still be a low-base artefact.

Keep these limits visible

A high growth rate can be a low-base artefact. The page keeps level and change separate for that reason.
A high ROCE can be temporary or flattered by a small capital base. Read it beside margin, cash conversion and reinvestment.
The 4-Factor Sector Score ranks research priority, not portfolio action. Management quality, catalysts and risks need equally fresh evidence before capital is deployed.
An “all companies” line chart preserves completeness, but rank changes should be checked against reporting dates before drawing a conclusion.
2 companies are missing from the second-feed metrics by decision, not by absence: the two sources disagree, so nothing from the second is drawn. Read those rows as narrower evidence, never as a weaker business.

13 · evidence and freshness

How was this comparison built?

This comparison is built from the reported filings of 8 Pharma - MNC bulk Drugs companies, normalized to a common ₹ scale and a shared quarter axis of up to 20 quarters each. Fundamentals run through Jun 2026 and market data through 2026-09-11.

FundamentalsThrough Jun 2026 · up to 20 quarters per company

Market dataThrough 2026-09-11 · weekly price and relative-strength history

Derived metricsGrowth, changes and PEG are calculated only when their inputs are comparable.

Score confidenceMissing and stale evidence reduces confidence and pulls the 0–100 research-priority score toward neutral.

Source standing6 cross-checked · 0 unverified · 2 withheld, of 8 graded companies.

How a second data feed is admitted, and what happens when it disagrees

A second feed is read only after its reported income is matched against the primary source on at least three overlapping periods. Where the two agree the figures fill silently. Where there is too little shared history to compare, the figures are still drawn — they are the only evidence there is — and marked ⚠ unverified everywhere they appear. Where the two are known to disagree, nothing from the second feed is drawn and the affected company is named under the chart it is missing from.

14 · questions investors ask, short speakable answers

Pharma - MNC bulk Drugs company comparison FAQs

These 24 answers restate the Pharma - MNC bulk Drugs comparison above in question form. Every one is computed from the same 8 companies and the same reported filings as the rankings and charts, current through Jun 2026. Price and relative-strength answers run through 2026-09-11. Nothing here is estimated, and none of it is a recommendation.

Is the Pharma - MNC bulk Drugs sector outperforming NIFTY 500?

Pharma - MNC bulk Drugs has outperformed NIFTY 500 by 0% over 52 weeks and 6.5% over 13 weeks. 2 of 8 covered companies beat NIFTY on Mansfield relative strength, while 3 of 8 beat the sector itself.

Which Pharma - MNC bulk Drugs company is largest by revenue?

Abbott India Ltd leads with revenue of ₹7,005 crore, based on 8 of 8 comparable companies through Jun 2026.

Which Pharma - MNC bulk Drugs company is growing fastest?

Astrazeneca Pharma India Ltd has the fastest current revenue growth at 31.2%, across 8 of 8 comparable companies.

Which Pharma - MNC bulk Drugs company has the strongest 4-Factor Sector Score?

Procter & Gamble Health Ltd ranks first at 65.6/100 with 94% evidence confidence. The score prioritizes research; it is not a buy recommendation.

Which Pharma - MNC bulk Drugs company has the lowest comparable PEG?

Pfizer Ltd has the lowest comparable PEG at 0.73, among 6 of 8 companies whose earnings and growth are steady enough for the ratio to mean anything.

How much history does this Pharma - MNC bulk Drugs comparison include?

The page compares up to 20 reported quarters per company for fundamentals, returns and valuation, ending Jun 2026. Missing observations remain blank rather than being estimated.

How is the 4-Factor Sector Score calculated?

The four visible contributions add directly: growth and earnings up to 35 points, capital efficiency up to 25, valuation up to 20, and relative strength up to 20. Missing or stale evidence moves only the affected contribution toward neutral.

Is there a Nifty Pharma - MNC bulk Drugs index?

NSE India maintains Nifty indices for several broad sector categories — Nifty Bank, Nifty IT, Nifty Pharma and others — but not for every sub-sector grouping on this site. Whether or not an official Nifty index covers Pharma - MNC bulk Drugs, this page builds its own equal-weight basket of 8 listed Pharma - MNC bulk Drugs companies — one company, one vote, regardless of market value — so no single large company dominates the reading. Figures are as of Jun 2026.

Which are the best Pharma - MNC bulk Drugs stocks in India?

Ranked by this page's four-factor score, Procter & Gamble Health Ltd places first among 8 listed Pharma - MNC bulk Drugs companies, followed by Sanofi Consumer Healthcare India Ltd. That is a ranking of published data — earnings, quality, valuation and market behaviour as of Jun 2026 — and not a recommendation; Sector Alpha is not registered with SEBI as an investment adviser.

How many Pharma - MNC bulk Drugs stocks are listed in India?

This comparison covers 8 listed Pharma - MNC bulk Drugs companies in India, each above the size floor the site applies, with 20 quarters of reported figures per company where the filings exist. The full ranked list is on this page, as of Jun 2026.

Which Pharma - MNC bulk Drugs company is the biggest?

Abbott India Ltd is the largest, with trailing-twelve-month revenue of ₹7,005 crore, ahead of Glaxosmithkline Pharmaceuticals Ltd at ₹3,954 crore. That covers 8 of 8 companies with comparable reporting through Jun 2026.

Which Pharma - MNC bulk Drugs company has the best profit margins?

Pfizer Ltd has the highest operating margin at 38%, from 8 of 8 comparable companies. Sanofi Consumer Healthcare India Ltd shows the biggest recent improvement, at +6 percentage points. A high margin matters most when it is holding or rising, not when it is peaking.

Which Pharma - MNC bulk Drugs company makes the most profit?

Abbott India Ltd earns the most, at ₹1,615 crore of trailing-twelve-month net profit, from 8 of 8 comparable companies. Sanofi Consumer Healthcare India Ltd has the fastest profit growth at 33%, though growth off a small or recovering profit base overstates how much has actually changed.

Which Pharma - MNC bulk Drugs company earns the highest return on capital?

Sanofi Consumer Healthcare India Ltd leads on return on capital employed at 89.9%, across 8 of 8 companies. Read it beside the length of its reported history: a high return that repeats for years is evidence of a durable business, while a single high reading can be a small capital base or one good year.

Which Pharma - MNC bulk Drugs stock is the cheapest?

On PEG — where a LOWER number is cheaper — Pfizer Ltd screens cheapest at 0.73×. Only 6 of 8 companies have earnings and growth steady enough for the ratio to mean anything, so this is not a sector-wide "cheapest stock" verdict. Cheap on a multiple is a reason to investigate, never a reason to buy on its own.

Is the Pharma - MNC bulk Drugs sector beating the market?

Pharma - MNC bulk Drugs has outperformed NIFTY 500 by 0% over the last 52 weeks and 6.5% over 13 weeks, measured on an equal-weight index of its current members. Inside the sector, 2 of 8 covered companies are beating the market on their own. Sector strength does not transfer evenly to every stock in it.

Which Pharma - MNC bulk Drugs stock has the strongest price momentum?

Novartis India Ltd has the strongest relative strength against NIFTY 500. Relative strength answers last, after growth, quality and valuation: price can move well before the fundamentals confirm it, and sometimes without them confirming at all.

Which Pharma - MNC bulk Drugs company scores highest for research priority?

Procter & Gamble Health Ltd scores 65.6 out of 100 with 94% evidence confidence, from 25.1 points on growth and earnings, 18.4 on capital efficiency, 13.3 on valuation and 8.8 on relative strength. This ranks what deserves work next. It is not a buy recommendation, and management quality, catalysts and risk still need separate research.

How many Pharma - MNC bulk Drugs companies does this comparison cover, and over what period?

It compares 8 listed companies over up to 20 reported quarters of fundamentals, ending Jun 2026, plus weekly price and relative-strength history. Membership is the full sector list — nothing is dropped for having thin data.

What is the total market cap of the Pharma - MNC bulk Drugs sector?

The 8 Pharma - MNC bulk Drugs companies on this page carry ₹1,68,938 crore of combined market value. Abbott India Ltd is the largest at ₹54,294 crore, about 32% of the sector's total on its own. Market value moves with price, so this reading is dated 2026-09-17.

What is the Pharma - MNC bulk Drugs sector's P/E ratio?

The median price-to-earnings ratio across the 8 Pharma - MNC bulk Drugs companies on this page is 34.8×, measured on the 8 that report a comparable figure. A sector-level history for this multiple is not held here, so this is a cross-section of today, not a comparison with the sector’s own past. Figures are as of 2026-09-17.

How is the Pharma - MNC bulk Drugs sector performing?

2 of the 8 covered Pharma - MNC bulk Drugs companies are beating NIFTY 500 on Mansfield relative strength. The sector itself is 0% ahead of NIFTY 500 over 52 weeks on an equal-weight index of its current members. Readings are as of 2026-09-17.

Why are some values on this page blank?

A blank means that company did not report a comparable figure for that period, so nothing is shown. Missing observations are never interpolated, carried forward, or replaced with a similar-looking accounting line, and a company with missing evidence has its research score pulled toward neutral rather than being scored as bad.

Is this investment advice?

No. Every figure here is a deterministic calculation from reported company filings and market data, published for research. It contains no recommendation to buy or sell any security, does not account for your circumstances, and is not a substitute for advice from a licensed adviser.

About

Not SEBI Registered !! Not Investment advice !!